These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21830453)

  • 1. Treatment of ovarian hyperstimulation syndrome: new insights.
    Kasum M; Oresković S
    Acta Clin Croat; 2010 Dec; 49(4):421-7. PubMed ID: 21830453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
    Chen SU; Chou CH; Lin CW; Lee H; Wu JC; Lu HF; Chen CD; Yang YS
    Hum Reprod; 2010 Mar; 25(3):757-67. PubMed ID: 20008399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights in prediction of ovarian hyperstimulation syndrome.
    Kasum M; Oresković S
    Acta Clin Croat; 2011 Jun; 50(2):281-8. PubMed ID: 22263397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology and pathology of ovarian hyperstimulation syndrome.
    Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
    Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of ovarian hyperstimulation syndrome.
    Dourron NE; Williams DB
    Semin Reprod Endocrinol; 1996 Nov; 14(4):355-65. PubMed ID: 8988530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ovarian hyperstimulation syndrome].
    Le Gouez A; Naudin B; Grynberg M; Mercier FJ
    Ann Fr Anesth Reanim; 2011 Apr; 30(4):353-62. PubMed ID: 21398079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on management of ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Chao KH; Lien YR; Chen SU; Yang YS
    Taiwan J Obstet Gynecol; 2011 Mar; 50(1):2-10. PubMed ID: 21482366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of ovarian hyperstimulation syndrome.
    Vlahos NF; Gregoriou O
    Ann N Y Acad Sci; 2006 Dec; 1092():247-64. PubMed ID: 17308149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights in mechanisms for development of ovarian hyperstimulation syndrome.
    Kasum M
    Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the high-risk patient for ovarian hyperstimulation syndrome.
    Papanikolaou EG; Humaidan P; Polyzos NP; Tarlatzis B
    Semin Reprod Med; 2010 Nov; 28(6):458-62. PubMed ID: 21082503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ovarian hyperstimulation syndrome. Current concepts].
    Kably Ambe A; Sinibaldi Gómez J; Rosete Rossetti R; Barrón Vallejo J; Serviere Zaragoza C; Villavicencio Castañeda J
    Ginecol Obstet Mex; 1994 Apr; 62():98-102. PubMed ID: 8034223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
    Kashyap S; Parker K; Cedars MI; Rosenwaks Z
    Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome.
    Griesinger G; Dafopoulos K; Schultze-Mosgau A; Jelkmann W; von Otte S; Diesing D; Diedrich K
    Arch Gynecol Obstet; 2006 Apr; 274(1):29-33. PubMed ID: 16408189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
    Kalampokas T; Creatsas G; Kalampokas E
    Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome.
    Villasante A; Pacheco A; Pau E; Ruiz A; Pellicer A; Garcia-Velasco JA
    Hum Reprod; 2008 Mar; 23(3):662-7. PubMed ID: 18216038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.